Summary

KEY FINDINGS
As per Inkwood Research, the global dry eye disease market is expected to grow at a CAGR of 5.02% during the period from 2024 to 2032. The market was valued at $5673.53 million in 2023, reaching a revenue of $8884.34 million by 2032.
Dry eye disease is a chronic, progressive syndrome affecting millions globally, with the incidence rising significantly with age. As the global population ages, and with longer life spans, the demand for effective dry eye disease treatment devices and products is escalating. In rapidly emerging economies, the expansion of wealthier, professional, and urban populations is further fueling this demand, as these groups have better access to healthcare and are more likely to seek treatment.
Technological advancements are playing a crucial role in the dry eye disease industry. For instance, Johnson & Johnson’s subsidiary, TearScience, has introduced the LipiView II Ocular Surface Interferometer and the LipiScan Dynamic Meibomian Imager, which have revolutionized dry eye disease diagnosis by providing sophisticated assessments and aiding in accurate identification of the disease. Additionally, in April 2022, Alcon launched the Systane® iLux2® Meibomian Gland Dysfunction Thermal Pulsation System, which features cutting-edge imaging technology. This all-in-one handheld device not only improves treatment outcomes but also allows patients to visualize the need for treatment, leading to noticeable results within a week. Such advancements have increased the demand for dry eye disease treatment drugs and products.
Despite these advancements, the dry eye disease market faces several challenges. The risk of side effects from eye drops for dry eye disease, including blurred vision, redness, and eyelid swelling, remains a concern. Additionally, the high costs of specialized products and the complexity of reimbursement scenarios pose significant barriers to market growth.
The recent cases of infections and vision loss linked to contaminated eye drops, including three fatalities confirmed by the CDC in 2023, further highlight the need for safer and more effective treatment options. However, the increasing prevalence of dry eye disease combined with continuous innovation in diagnostic and therapeutic products positions the market for sustained growth.
MARKET INSIGHTS
Key growth enablers of the global dry eye disease market:
• Rising incidence and prevalence of dry eye among various age groups
o The National Institute of Health has identified dry eye disease (DED) as one of the most common ocular conditions globally. In populous countries like China, the prevalence of this disease is particularly high. Factors such as changes in lifestyle and an aging population have contributed to DED becoming a significant public health concern. A 2017 report from the Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) Epidemiology subcommittee indicated that individuals of Asian descent are more susceptible to dry eye disease, with an estimated prevalence of around 17.0% in the region.
o The TFOS Dry Eye Workshop II, also conducted in 2017, found that the prevalence of DED was increasing among individuals aged 40-49. Among women, the prevalence ranged from 14% in those aged 50 to 22% in those aged 80 and older. In men, the disease tends to manifest later and less frequently, with a prevalence of approximately 7% in men aged 60-69 and 13% in those aged 80 and above.
o Dry eye disease is also common in developed countries like the United States, where healthcare systems are well established. According to a 2019 study by Reza Dana et al., published in the American Journal of Ophthalmology, the overall prevalence of DED was 5.28%, with a higher prevalence among female beneficiaries (7.78%) compared to male beneficiaries (2.96%).
o The study also observed that the prevalence of DED increases with age, from 0.20% in individuals aged 2-17 years to 11.66% in those aged 50 and above. However, various regions around the world are taking steps to address the rising prevalence of DED. For example, the European Society of Cataract and Refractive Surgeons is focusing on mitigating the impact of DED to ensure that the quality of life in Europe is not adversely affected.
• Launch of pipeline products for the treatment of dry eye disease
• Introduction of new diagnostic techniques for dry eye disease
Key restraining factors of the global dry eye disease market:
• Risk of side effects associated with treatments
• Availability of alternative therapies
o Dry eye disease has garnered increased attention from ophthalmologists due to its rising prevalence. In the therapeutic market, the availability of medications for dry eye disease (DED) has expanded, making it easier for individuals to access appropriate treatments. These factors are contributing to the growth of the DED market. However, some individuals prefer alternative treatment methods driven by concerns over health and potential side effects associated with certain medications.
o Natural treatment options have gained traction as potential remedies for DED. For example, research conducted on Korean adults has suggested that vitamin D deficiency may contribute to DED, and supplementing with vitamin D has been shown to alleviate symptoms in some cases. Another natural remedy includes the use of Omega-3 fatty acids. According to a study published in Medical Science Monitor, supplementation with Omega-3 fatty acids has been linked to improvements in dry eye symptoms among affected individuals.
o Additionally, various procedures are available to treat DED, depending on the severity of the condition. These include methods like closing the tear ducts to minimize tear loss, using specialized contact lenses, unblocking oil glands, and employing light therapy or eyelid massage. Other commonly used alternative treatments include acupuncture, castor oil eye drops, mild soap for cleaning the eyelids and applying a warm cloth to the eyelids. While these alternative treatments offer additional options, their availability may have a moderating effect on the overall growth of the DED market.
• High costs of specialty products and a complex reimbursement landscape
Global Dry Eye Disease Market | Top Trends
• Emerging developments in stem cell therapy are being explored for the treatment of Dry Eye Disease (DED). The primary goal of this research is to slow disease progression, encourage tissue regeneration, and maintain corneal clarity. Researchers are particularly focusing on the use of cytokines and various cell sources, such as mesenchymal stem cells, as potential approaches to treating DED. In April 2022, a study led by scientists at Osaka University in Japan, in collaboration with researchers from Cardiff University’s School of Optometry and Vision Sciences, investigated the generation of miniature lacrimal glands using human induced pluripotent stem (iPS) cells. These iPS cells, derived from mature skin cells, were cultured under defined laboratory conditions to form two-dimensional cell clusters that partially mimic human eye development. From these clusters, cells resembling lacrimal gland precursor cells were extracted and further cultured in three dimensions to create tissue organoids that resemble lacrimal glands. This research represents a potential new avenue in addressing the effects of dry eye disease.
SEGMENTATION ANALYSIS
Market Segmentation – Type, Product, Dosage, and Distribution Channel –
Market by Type:
• OTC
o OTC is expected to be the dominating type during the forecast period, capturing the highest market share of 58.60% by 2032.
o In the current context, prolonged exposure to computer screens is a significant contributor to eye strain and dryness, conditions often treated with eye drops. Non-prescription eye drops are available over the counter and commonly contain ingredients such as humectants, which help retain moisture, lubricants, and electrolytes like potassium. These drops can be used as directed to provide temporary relief from dry eye symptoms.
o Compared to prescription medications, over-the-counter (OTC) eye drops are generally more affordable. However, they typically offer only short-term relief and primarily target the tear film’s aqueous layer, providing limited effectiveness in addressing dry eye disease.
o Many OTC eye drops include non-blurring lubricants designed to offer longer-lasting relief from symptoms such as burning and stinging, which may be caused by factors like excessive digital media use, extended contact lens wear, laser eye surgery, hormonal changes, or dry environments.
o Popular OTC eye drops include VISINE eye drops, Refresh Tears lubricant eye drops, and Systane ultra-lubricant eye drops. The demand for OTC medications is expected to grow during the forecast period, driven by their easy availability and relatively low cost.
• Prescription
Market by Product:
• Anti-Inflammatory Drugs
o Cyclosporine
o Corticosteroid
 Corticosteroids are effective anti-inflammatory drugs, widely available, that rapidly relieve the symptoms and signs of moderate and severe dry eye. These drugs are highly useful in short-term efficacy; thus, they are prescribed mostly for acute cases of dry eye diseases. However, with the long-term usage of these drugs, there are major side effects, such as intraocular pressure elevation and cataract progression.
 Topical antibiotic-corticosteroid combination products are useful for decreasing bacterial load and managing inflammation. Concerns regarding antibiotic resistance and long-term exposure to corticosteroids are the drawbacks of these medications. Two major companies established in this segment are Bausch Health and Allergan (now part of AbbVie Inc).
 Often, these companies, as well as doctors, recommend corticosteroids along with antibiotic therapy. Some off-label drugs, such as loteprednol (lotemax) therapy for inflammation, are also very effective. The topical nature of these drugs is also useful in suppressing acute environmentally induced ocular surface inflammation.
 Moreover, new entrants in the market are focusing on developing new formulations based on steroids to treat DES. For instance, in March 2020, Kala Pharmaceuticals announced the preliminary results of an additional clinical trial performed to study the efficacy of its product, Inveltys, on relieving signs and symptoms of dry eye disease temporarily, and the company is planning to resubmit the regulatory filing based on new data to the FDA. In October 2020, the United States Food and Drug Administration (FDA) approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis, Kala Pharmaceuticals Inc) for the signs and symptoms of dry eye disease.
o Other Anti-Inflammatory Drugs
• Artificial Tears
• Punctal Plugs
• Secretagogues
• Other Products
Market by Dosage:
• Eye Drops
• Eye Solutions
• Ointments
• Gels
• Capsules & Tablets
Market by Distribution Channel:
• Hospital Pharmacies
• Independent Pharmacies and Drug Stores
• Online Pharmacies/Stores
REGIONAL ANALYSIS
Geographical Study Based on Four Major Regions:
• North America: The United States and Canada
• Europe: The United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe
• Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific
o The Asia-Pacific dry eye disease market is expected to be the leading region, progressing with the highest CAGR of 5.51% between 2024 to 2032.
o The region’s dry eye disease market is characterized by a growing patient population due to increasing screen time, aging demographics, and rising awareness about ocular health. Urbanization and lifestyle changes have contributed to a higher prevalence of dry eye disease, particularly in countries such as China, Japan, and India.
o Increased adoption of digital devices is a significant factor, with studies indicating that over 60% of adults in urban areas report symptoms associated with dry eye disease.
o Additionally, the region is witnessing a steady increase in the number of individuals over 50 years old, a demographic particularly susceptible to this condition. A study revealed that nearly 30% of individuals in this age group experience moderate to severe symptoms. Furthermore, the region has reported a 20% rise in healthcare expenditure related to eye health over the past five years, emphasizing the growing concern and demand for treatment.
o Initiatives to improve healthcare access and the availability of advanced treatment options are supporting market growth. Pharmaceutical advancements and the development of new therapeutic options, including artificial tears and anti-inflammatory medications, are providing better management for patients.
• Rest of World: Latin America, the Middle East & Africa
Our market research reports offer an in-depth analysis of individual country-level market size and growth statistics. We cover the segmentation analysis, key growth factors, and macro-economic trends within the dry eye disease market, providing detailed insights into –
• Japan Dry Eye Disease Market
• The United States Dry Eye Disease Market
• China Dry Eye Disease Market
COMPETITIVE INSIGHTS
Major players in the global dry eye disease market:
• Alcon
• Allergan Plc (Acquired by Abbvie)
• Bausch Health Companies Inc
• Johnson & Johnson
• AFT Pharmaceuticals
Key strategies adopted by some of these companies;
• In May 2023, Bausch + Lomb Corporation and Novaliq GmbH announced the approval of MIEBO by the US Food and Drug Administration (FDA) for the treatment of dry eye disease.
• Visiox Pharma Inc announced a definitive agreement with Santen Pharmaceutical Co Ltd in July 2023 to license OMLONTI 0.002%. The product also received approval from the US Food and Drug Administration.
• In May 2023, the FDA approved Miebo, a treatment developed by Bausch + Lomb and Novaliq, for addressing the signs and symptoms of dry eye disease by reducing tear evaporation, which is a primary factor in the condition.
• Sun Pharma, in January 2022, launched its treatment product, Cequa, in Canada. This product utilizes Nanomicellar (NCELL) technology, which enhances the bioavailability and physicochemical stability of cyclosporine and improves its penetration into the eye tissue.
• Aldeyra Therapeutics Inc completed a phase 3 clinical trial for 0.25% reproxalap ophthalmic solution in October 2022, an investigational drug candidate for the treatment of allergic conjunctivitis. The company presented the clinical data from this trial at the American Academy of Optometry 2022 Annual Meeting.
We Offer 10% Free Customization and 3 Months Analyst Support
Frequently Asked Questions (FAQs):
• What are the common symptoms of dry eye disease?
A: The symptoms of dry eye disease include dryness, irritation, a gritty or sandy feeling, burning, redness, blurred vision, sensitivity to light, and excessive tearing (which is a response to irritation).
• What causes dry eye disease?
A: The causes of dry eye disease include aging, hormonal changes, certain medications, environmental factors (like wind or smoke), prolonged screen time, contact lens wear, and underlying medical conditions such as autoimmune diseases.
• What are the treatment options for dry eye disease?
A: The treatment options for dry eye disease include artificial tears, prescription eye drops, lifestyle changes, warm compresses, omega-3 supplements, and, in some cases, procedures like punctal plugs or intense pulsed light therapy.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE DRY EYE DISEASE MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. PROLONGED SCREEN EXPOSURE CAN TRIGGER SYMPTOMS OF DRY EYE
2.5.2. INDIVIDUALS OF ASIAN DESCENT ARE MORE SUSCEPTIBLE TO DEVELOPING DRY EYE DISEASE
2.5.3. AIR POLLUTION IS A SIGNIFICANT CONTRIBUTOR TO EYE-RELATED CONDITIONS
2.5.4. THE COVID-19 PANDEMIC HAS LED TO A SURGE IN DRY EYE DISEASE CASES
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. RISING INCIDENCE AND PREVALENCE OF DRY EYE AMONG VARIOUS AGE GROUPS
3.1.2. LAUNCH OF PIPELINE PRODUCTS FOR THE TREATMENT OF DRY EYE DISEASE
3.1.3. INTRODUCTION OF NEW DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS ASSOCIATED WITH TREATMENTS
3.2.2. AVAILABILITY OF ALTERNATIVE THERAPIES
3.2.3. HIGH COSTS OF SPECIALTY PRODUCTS AND A COMPLEX REIMBURSEMENT LANDSCAPE
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.2.1. EMERGING STEM CELL THERAPY IN THE TREATMENT OF DRY EYE DISEASE
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.4.1. GROWTH PROSPECT MAPPING FOR NORTH AMERICA
4.4.2. GROWTH PROSPECT MAPPING FOR EUROPE
4.4.3. GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
4.4.4. GROWTH PROSPECT MAPPING FOR REST OF WORLD
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DOSAGE
7.1. EYE DROPS
7.2. EYE SOLUTIONS
7.3. OINTMENTS
7.4. GELS
7.5. CAPSULES & TABLETS
8. MARKET BY DISTRIBUTION CHANNEL
8.1. HOSPITAL PHARMACIES
8.2. INDEPENDENT PHARMACIES AND DRUG STORES
8.3. ONLINE PHARMACIES/STORES
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. NORTH AMERICA DRY EYE DISEASE MARKET DRIVERS
9.1.3. NORTH AMERICA DRY EYE DISEASE MARKET CHALLENGES
9.1.4. NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
9.1.5. KEY PLAYERS IN NORTH AMERICA DRY EYE DISEASE MARKET
9.1.6. COUNTRY ANALYSIS
9.1.6.1. UNITED STATES
9.1.6.1.1. UNITED STATES DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.1.6.2. CANADA
9.1.6.2.1. CANADA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.2. EUROPE
9.2.1. MARKET SIZE & ESTIMATES
9.2.2. EUROPE DRY EYE DISEASE MARKET DRIVERS
9.2.3. EUROPE DRY EYE DISEASE MARKET CHALLENGES
9.2.4. EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
9.2.5. KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET
9.2.6. COUNTRY ANALYSIS
9.2.6.1.1. UNITED KINGDOM
9.2.6.1.1.1. UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.2.6.2. GERMANY
9.2.6.2.1.1. GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.2.6.3. FRANCE
9.2.6.3.1.1. FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.2.6.4. ITALY
9.2.6.4.1. ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.2.6.5. SPAIN
9.2.6.5.1. SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.2.6.6. BELGIUM
9.2.6.6.1. BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.2.6.7. POLAND
9.2.6.7.1. POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.2.6.8. REST OF EUROPE
9.2.6.8.1. REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.3. ASIA-PACIFIC
9.3.1. MARKET SIZE & ESTIMATES
9.3.2. ASIA-PACIFIC DRY EYE DISEASE MARKET DRIVERS
9.3.3. ASIA-PACIFIC DRY EYE DISEASE MARKET CHALLENGES
9.3.4. ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
9.3.5. KEY PLAYERS IN ASIA-PACIFIC DRY EYE DISEASE MARKET
9.3.6. COUNTRY ANALYSIS
9.3.6.1. CHINA
9.3.6.1.1. CHINA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.3.6.2. JAPAN
9.3.6.2.1. JAPAN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.3.6.3. INDIA
9.3.6.3.1. INDIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.3.6.4. SOUTH KOREA
9.3.6.4.1. SOUTH KOREA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.3.6.5. THAILAND
9.3.6.5.1. THAILAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.3.6.6. VIETNAM
9.3.6.6.1. VIETNAM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.3.6.7. INDONESIA
9.3.6.7.1. INDONESIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.3.6.8. AUSTRALIA & NEW ZEALAND
9.3.6.8.1. AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.3.6.9. REST OF ASIA-PACIFIC
9.3.6.9.1. REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.4. REST OF WORLD
9.4.1. MARKET SIZE & ESTIMATES
9.4.2. REST OF WORLD DRY EYE DISEASE MARKET DRIVERS
9.4.3. REST OF WORLD DRY EYE DISEASE MARKET CHALLENGES
9.4.4. REST OF WORLD DRY EYE DISEASE REGULATORY FRAMEWORK
9.4.5. KEY PLAYERS IN REST OF WORLD DRY EYE DISEASE MARKET
9.4.6. REGIONAL ANALYSIS
9.4.6.1. LATIN AMERICA
9.4.6.1.1. LATIN AMERICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.4.6.2. MIDDLE EAST & AFRICA
9.4.6.2.1. MIDDLE EAST & AFRICA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. ALCON
10.2.1.1. COMPANY OVERVIEW
10.2.1.2. PRODUCT LIST
10.2.1.3. STRENGTHS & CHALLENGES
10.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE)
10.2.2.1. COMPANY OVERVIEW
10.2.2.2. PRODUCT LIST
10.2.2.3. STRENGTHS & CHALLENGES
10.2.3. BAUSCH HEALTH COMPANIES INC
10.2.3.1. COMPANY OVERVIEW
10.2.3.2. PRODUCT LIST
10.2.3.3. STRENGTHS & CHALLENGES
10.2.4. JOHNSON & JOHNSON
10.2.4.1. COMPANY OVERVIEW
10.2.4.2. PRODUCT LIST
10.2.4.3. STRENGTHS & CHALLENGES
10.2.5. AFT PHARMACEUTICALS
10.2.5.1. COMPANY OVERVIEW
10.2.5.2. PRODUCT LIST
10.2.5.3. STRENGTHS & CHALLENGES
10.2.6. LUMENIS
10.2.6.1. COMPANY OVERVIEW
10.2.6.2. PRODUCT LIST
10.2.6.3. STRENGTHS & CHALLENGES
10.2.7. NOVALIQ GMBH
10.2.7.1. COMPANY OVERVIEW
10.2.7.2. PRODUCT LIST
10.2.7.3. STRENGTHS & CHALLENGES
10.2.8. OASIS MEDICAL
10.2.8.1. COMPANY OVERVIEW
10.2.8.2. PRODUCTS LIST
10.2.8.3. STRENGTHS & CHALLENGES
10.2.9. OTSUKA PHARMACEUTICAL CO LTD
10.2.9.1. COMPANY OVERVIEW
10.2.9.2. PRODUCT LIST
10.2.9.3. STRENGTHS & CHALLENGES
10.2.10. SANTEN PHARMACEUTICAL CO LTD
10.2.10.1. COMPANY OVERVIEW
10.2.10.2. PRODUCTS LIST
10.2.10.3. STRENGTHS & CHALLENGES
10.2.11. NOVARTIS AG
10.2.11.1. COMPANY OVERVIEW
10.2.11.2. PRODUCT LIST
10.2.11.3. STRENGTHS & CHALLENGES
10.2.12. SENTISS PHARMA PRIVATE LIMITED
10.2.12.1. COMPANY OVERVIEW
10.2.12.2. PRODUCTS LIST
10.2.12.3. STRENGTHS & CHALLENGES
10.2.13. TEVA PHARMACEUTICAL INDUSTRIES LTD
10.2.13.1. COMPANY OVERVIEW
10.2.13.2. PRODUCT LIST
10.2.13.3. STRENGTHS & CHALLENGES
10.2.14. SUN PHARMACEUTICAL INDUSTRIES LTD
10.2.14.1. COMPANY OVERVIEW
10.2.14.2. PRODUCT LIST
10.2.14.3. STRENGTHS & CHALLENGES
10.2.15. VISUFARMA
10.2.15.1. COMPANY OVERVIEW
10.2.15.2. PRODUCT LIST
10.2.15.3. STRENGTHS & CHALLENGES